EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES (EEJMMS)
ISSN: 2992-4103
©EEJMMS Publications Volume 6 Issue 3 2025

Targeting Obesity-Linked Diabetes and Cancer: Synergistic Roles of Natural Antioxidants and Nanotechnology-Based Drug Delivery Systems

Omeye Francis I.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Obesity is a multifactorial metabolic disorder associated with an increased risk of chronic diseases such as type 2 diabetes mellitus (T2DM) and various cancers. The pathophysiological connection among these disorders is primarily mediated by chronic inflammation, oxidative stress, insulin resistance, and dysregulated adipokine signaling. Natural antioxidants derived from plant-based sources exhibit potent bioactive properties capable of modulating oxidative and inflammatory pathways implicated in obesity-related metabolic diseases and malignancies. However, their therapeutic application is limited by poor bioavailability, stability, and targeted delivery. Nanotechnology-based drug delivery systems offer innovative platforms to overcome these barriers, enhancing the pharmacokinetic and pharmacodynamic profiles of natural antioxidants. This review highlights the mechanistic link between obesity, diabetes, and cancer, evaluates the therapeutic potential of natural antioxidants, and explores advanced nanotechnology-based delivery strategies to improve efficacy. The synergistic application of antioxidants and nanomedicine holds significant promise for integrated, precise, and targeted treatment of obesity-related chronic diseases.

Keywords: Obesity, Diabetes, Cancer, Natural Antioxidants, Nanotechnology, Drug Delivery Systems, Oxidative Stress, Inflammation, Phytochemicals, Targeted Therapy

INTRODUCTION

Obesity has emerged as a formidable global health challenge, transcending geographical, socioeconomic, and age boundaries[1–3]. The World Health Organization estimates that more than 1.9 billion adults are overweight, with over 650 million classified as obese. This exponential rise in obesity prevalence has significantly contributed to the global burden of non-communicable diseases (NCDs), notably type 2 diabetes and various forms of cancer[4]. The interrelationship between obesity, diabetes, and cancer collectively referred to as the obesity-diabetes-cancer triad represents a multifactorial public health concern[5]. Epidemiological studies underscore that individuals with obesity are at a higher risk of developing insulin resistance and chronic hyperglycemia, which in turn are linked to increased susceptibility to certain cancers such as colorectal, breast, and pancreatic malignancies[2, 6, 7]. The mechanistic overlaps between these conditions suggest a shared pathogenic trajectory, thereby reinforcing the need for integrated preventive and therapeutic strategies.

The pathophysiological basis of this triad lies in a convergence of several molecular mechanisms, primarily involving chronic low-grade inflammation, insulin resistance, and oxidative stress. In the context of obesity, dysfunctional adipose tissue becomes a reservoir for pro-inflammatory cytokines and chemokines that disturb metabolic homeostasis and compromise immune surveillance[3, 8, 9]. These inflammatory signals not only impair insulin receptor signaling, thus precipitating insulin resistance and type 2 diabetes but also enhance cell proliferation, inhibit apoptosis, and stimulate angiogenesis, thereby fostering a pro-tumorigenic microenvironment[10, 11]. Oxidative stress, largely driven by mitochondrial dysfunction and hyperglycemia, exacerbates cellular damage by promoting reactive oxygen species (ROS) accumulation, DNA damage, and mutations in oncogenes and tumor suppressor genes[12–14]. These processes reinforce a pathological loop that propels the transition from metabolic disorders to malignancy.

Conventional pharmacotherapies aimed at managing obesity, diabetes, and cancer are often hampered by significant drawbacks, including drug resistance, systemic toxicity, and diminished efficacy over time. This has prompted a paradigm shift towards alternative and adjunctive therapies that are both safer and more sustainable. Among such candidates, natural antioxidants have gained prominence due to their ability to neutralize ROS,

suppress inflammatory mediators, and restore cellular redox balance. These bioactive compounds found in fruits, vegetables, and medicinal plants exhibit chemopreventive and metabolic regulatory effects that may interrupt the pathological continuum of the obesity-diabetes-cancer axis[15]. Recent advances in nanotechnology have further revolutionized the delivery of these natural antioxidants, offering enhanced bioavailability, targeted delivery, and sustained release[10, 12, 16–20]. This integration of nanotechnology with antioxidant therapy represents a promising frontier in disrupting the molecular interplay that drives metabolic and neoplastic diseases. The current review synthesizes existing evidence on the mechanistic links between obesity, diabetes, and cancer, while highlighting the potential of nanotechnology-enhanced antioxidants as a novel interventional strategy.

2. Molecular Interlink between Obesity, Diabetes, and Cancer

The molecular interplay between obesity, diabetes, and cancer is deeply rooted in chronic inflammation and insulin resistance, which serve as pivotal drivers of metabolic and cellular dysfunction. In obesity, adipose tissue undergoes hypertrophy and hyperplasia, leading to mechanical and metabolic stress that activates resident macrophages[3, 9]. These immune cells switch to a pro-inflammatory M1 phenotype, secreting cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). These cytokines disrupt insulin receptor substrate (IRS) signaling pathways, impair glucose uptake, and promote systemic insulin resistance[9, 21]. Simultaneously, these inflammatory mediators activate oncogenic transcription factors like NF-κB and STAT3, which regulate genes involved in cell proliferation, survival, and angiogenesis. This establishes a microenvironment conducive to malignant transformation, especially in insulin-sensitive tissues such as the liver, pancreas, and colon[22].

Insulin resistance, a hallmark of type 2 diabetes, exacerbates this oncogenic environment through sustained hyperinsulinemia. Elevated insulin levels increase the bioavailability of insulin-like growth factor-1 (IGF-1), a potent mitogen that activates PI3K/Akt and MAPK pathways, promoting cellular proliferation and inhibiting apoptosis[23]. In parallel, insulin resistance is associated with dyslipidemia, ectopic fat deposition, and lipotoxicity, which further aggravate metabolic derangements. These metabolic changes not only compromise glycemic control but also fuel cancer progression by enhancing energy supply to rapidly proliferating cells and fostering an anabolic state[24, 25]. The convergence of metabolic dysregulation and chronic inflammation thus bridges the gap between obesity, insulin resistance, and carcinogenesis, forming a self-perpetuating cycle that is difficult to interrupt with conventional treatment modalities.

Oxidative stress constitutes another crucial molecular link in this pathological axis. In obesity and diabetes, mitochondrial dysfunction, hyperglycemia, and elevated free fatty acids lead to increased generation of reactive oxygen species (ROS)[21, 26]. Excessive ROS not only inflict damage on cellular macromolecules including DNA, proteins, and lipids but also interfere with insulin signaling pathways by promoting serine phosphorylation of insulin receptor substrates. Moreover, oxidative stress activates redox-sensitive transcription factors like NF-κB and AP-1, which upregulate pro-inflammatory cytokines and oncogenes, further amplifying both metabolic and neoplastic processes. Oxidative DNA damage, if unrepaired, can lead to genomic instability, mutations in tumor suppressor genes like p53, and activation of oncogenes such as Ras[27]. These genetic alterations, in the context of a pro-inflammatory and insulin-resistant milieu, facilitate the clonal expansion of transformed cells. Thus, oxidative stress acts as both a trigger and amplifier of the molecular events that underpin the obesity-diabetes-cancer triad, highlighting the importance of antioxidant strategies in mitigating disease progression.

2.1 Adipokines and Hormonal Imbalances

Adipokines, primarily leptin and adiponectin, are bioactive peptides secreted by adipose tissue that play crucial roles in metabolic regulation and inflammation. In obesity, the balance and function of these adipokines are significantly altered, contributing to hormonal imbalances and associated metabolic disorders[28]. Leptin levels are typically elevated in obese individuals, a condition referred to as leptin resistance. This elevation, rather than promoting satiety and energy expenditure, paradoxically fails to regulate appetite effectively[28]. Moreover, high leptin concentrations are implicated in promoting angiogenesis, cellular proliferation, and chronic low-grade inflammation—all of which are risk factors for tumorigenesis and cancer progression. On the other hand, adiponectin, which exhibits anti-inflammatory, anti-atherogenic, and insulin-sensitizing properties, is usually reduced in obesity[29, 30]. Low levels of adiponectin impair insulin sensitivity and glucose metabolism, thereby increasing the risk of type 2 diabetes and other metabolic syndromes. Additionally, adiponectin has been shown to exert protective effects against tumor development and progression through its anti-proliferative and pro-apoptotic actions[3]. The imbalance between these two key adipokines not only contributes to metabolic dysfunction but also creates a pro-inflammatory and pro-tumorigenic environment. Understanding these hormonal alterations is critical for developing targeted therapies to mitigate obesity-related complications, including insulin resistance, cardiovascular diseases, and cancer.

3 Therapeutic Potential of Natural Antioxidants

3.1. Polyphenols

Polyphenols are a broad class of naturally occurring compounds found in fruits, vegetables, tea, wine, and other plant-based foods, known for their potent antioxidant properties[27, 27]. Among the most studied polyphenols are resveratrol, quercetin, curcumin, and epigallocatechin gallate (EGCG), each of which has shown significant promise in therapeutic contexts, particularly against diabetes and cancer. These compounds exert their beneficial effects primarily through the modulation of key cellular signaling pathways, including AMP-activated protein kinase (AMPK), phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), and apoptosis-related mechanisms[31, 32]. For instance, resveratrol activates AMPK and SIRT1, promoting improved insulin sensitivity and mitochondrial function. Similarly, curcumin modulates the PI3K/Akt pathway to inhibit tumor cell proliferation and induce apoptosis.

In cancer therapy, these polyphenols are recognized for their ability to interfere with multiple hallmarks of cancer, including evasion of apoptosis, sustained proliferation, and angiogenesis. EGCG, a green tea catechin, inhibits cancer cell growth by downregulating VEGF and suppressing the Akt pathway, which is often overactive in cancer cells[18]. Quercetin has shown to sensitize cancer cells to chemotherapeutic agents and induce cell cycle arrest. Beyond cancer and diabetes, these compounds also contribute to cardiovascular protection and neuroprotection[15]. Despite their compelling biological effects, the therapeutic application of polyphenols requires further optimization to overcome issues related to bioavailability and metabolic stability, which are discussed later in this outline.

3.2. Flavonoids

Flavonoids, a subclass of polyphenols, are widely distributed in nature and contribute to the vivid pigmentation of many fruits and vegetables[33]. These compounds have been extensively studied for their antioxidative, anti-inflammatory, and insulin-sensitizing properties. Their capacity to scavenge free radicals and upregulate endogenous antioxidant defenses such as superoxide dismutase and catalase makes them potent agents against oxidative stress—a key contributor to chronic diseases like diabetes and cancer[34]. In metabolic disorders, flavonoids enhance glucose uptake in peripheral tissues and modulate insulin signaling pathways, thereby improving glycemic control.

Recent research has also revealed the epigenetic modulatory potential of flavonoids in cancer prevention and therapy[35]. These compounds influence gene expression by altering DNA methylation, histone acetylation, and the activity of non-coding RNAs, all of which are crucial in regulating cell growth and apoptosis[35]. For instance, genistein and epicatechin gallate have been shown to demethylate tumor suppressor genes, thereby restoring their function. Moreover, flavonoids interact with transcription factors such as NF-κB and Nrf2, leading to downregulation of inflammatory cytokines and upregulation of cytoprotective genes[15]. These multifaceted actions make flavonoids valuable candidates for integrative medicine, though their efficacy in clinical settings still hinges on overcoming pharmacokinetic barriers.

3.3. Carotenoids and Terpenoids

Carotenoids, such as lycopene and beta-carotene, are lipid-soluble pigments found in tomatoes, carrots, and other brightly colored vegetables and fruits[36]. These compounds are renowned for their ability to reduce lipid peroxidation, a process that contributes to cellular damage in metabolic and degenerative diseases. In diabetes, carotenoids improve insulin sensitivity and reduce markers of oxidative stress. Lycopene, in particular, has been associated with a reduced risk of certain cancers, including prostate cancer, through mechanisms involving antioxidant activity and modulation of insulin-like growth factor signaling[37].

Terpenoids, a diverse class of organic compounds including ginsenosides and ursolic acid, exhibit a wide range of biological activities. These compounds have shown notable antiproliferative and pro-apoptotic effects on various cancer cell lines[37]. Ginsenosides from ginseng modulate cell cycle progression and promote apoptosis in tumor cells by influencing pathways such as MAPK and PI3K/Akt. Ursolic acid, found in apple peels and rosemary, suppresses tumor growth by inhibiting NF-κB and mTOR signaling[37–39]. Moreover, terpenoids have been observed to regulate glucose metabolism and enhance mitochondrial function, offering additional benefits for diabetic patients. Their dual role in combating both metabolic and oncological conditions highlights the potential of carotenoids and terpenoids as multifaceted natural therapeutics.

4. Limitations of Natural Antioxidants in Conventional Therapy

Despite their promising therapeutic potential, natural antioxidants face significant challenges in clinical application. One major limitation is their poor aqueous solubility, which restricts their absorption in the gastrointestinal tract and limits systemic availability[40]. Many of these compounds are lipophilic and require specialized delivery systems such as nanoparticles or liposomes for effective transport in the body. Additionally, they are often rapidly metabolized and cleared from the circulation, resulting in a short half-life and diminished therapeutic efficacy. For example, curcumin, despite its strong anticancer and anti-inflammatory activities in

vitro, exhibits very low plasma concentrations when administered orally, which hampers its clinical effectiveness[41].
Another critical drawback is the lack of tissue specificity[42]. Natural antioxidants typically act systemically and are not selectively accumulated in the target tissues, which can dilute their therapeutic impact and increase the risk of off-target effects. Moreover, their low oral bioavailability remains a persistent hurdle. Factors such as poor intestinal permeability, first-pass metabolism, and degradation by gut microbiota all contribute to their suboptimal pharmacokinetics[42]. To overcome these barriers, strategies including structural modification, use of adjuvants like piperine, and development of novel delivery platforms are being explored[43]. While the biological efficacy of natural antioxidants is well-established in preclinical models, translating these findings into clinically viable therapies requires a concerted effort in improving formulation, delivery, and dosing strategies.

5. Nanotechnology-Based Drug Delivery Systems

Nanotechnology has revolutionized drug delivery by enhancing the bioavailability, stability, and targeted delivery of therapeutic agents, particularly polyphenols[20]. Conventional delivery of polyphenolic compounds often suffers from limitations such as poor solubility, low permeability, and rapid metabolism. Nanocarrier systems offer innovative solutions by protecting these sensitive compounds and directing them to specific sites of action, which enhances therapeutic outcomes[44]. Various nanostructured platforms including polymeric nanoparticles, lipid-based nanocarriers, dendrimers, gold nanoparticles, nanoemulsions, and micelles are being explored for encapsulating antioxidants and polyphenols to treat metabolic and obesity-linked disorders[45]. These nanocarriers improve pharmacokinetics and pharmacodynamics through controlled release, surface modification for active targeting, and increased cellular uptake. Moreover, their small size allows them to cross biological barriers such as the gastrointestinal tract and blood-brain barrier, making them suitable for systemic and site-specific therapy. Functionalization with ligands, peptides, or antibodies can enable receptor-mediated endocytosis, thus enhancing specificity toward diseased tissues[46]. This section elaborates on the distinct types of nanocarriers, their mechanisms, and their potential applications in managing obesity-related diseases, diabetes, and cancers. Overall, nanotechnology-based systems represent a promising frontier in precision medicine, especially for bioactive compounds with known health benefits but limited clinical use due to poor bioavailability.

5.1. Polymeric Nanoparticles

Polymeric nanoparticles are one of the most widely studied nanocarriers for drug delivery, particularly in the encapsulation and controlled release of polyphenols.[47] Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and chitosan have gained popularity due to their biocompatibility, tunable degradation rates, and ability to protect labile compounds from premature degradation[48]. These polymers can encapsulate a wide variety of antioxidants and polyphenolic compounds, such as curcumin, quercetin, and resveratrol, thereby enhancing their solubility, bioavailability, and stability. Moreover, these nanoparticles can be engineered to achieve controlled or sustained drug release, thereby reducing dosing frequency and minimizing systemic toxicity[49]. Surface modification with ligands or antibodies enables active targeting, particularly to tissues overexpressing specific receptors, such as inflamed adipose tissue in obesity or tumor cells in cancer. Studies have shown that polymeric nanoparticles can improve intestinal absorption, prolong circulation time, and increase accumulation in target organs. This targeted delivery ensures that a greater proportion of the bioactive agent reaches the desired site, improving therapeutic efficacy. Polymeric nanoparticles also allow co-encapsulation of multiple therapeutic agents, offering synergistic effects in complex diseases such as metabolic syndrome or obesity-related cancer. These features make polymeric nanoparticles a highly promising tool in nanomedicine.

5.2. Lipid-Based Nanocarriers

Lipid-based nanocarriers such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) have emerged as highly effective systems for delivering hydrophobic antioxidants and polyphenols[17, 18]. These carriers are particularly useful for improving the solubility, stability, and permeability of lipophilic compounds that typically have low oral bioavailability. Liposomes consist of phospholipid bilayers that can encapsulate both hydrophilic and hydrophobic compounds, offering flexibility in drug loading. SLNs are made of solid lipids and provide a stable matrix for the encapsulation of poorly soluble bioactives[50]. NLCs, on the other hand, combine both solid and liquid lipids, offering improved drug loading capacity and controlled release profiles. These nanocarriers have shown great promise in crossing biological barriers, such as the gastrointestinal lining and the blood-brain barrier, thereby enhancing systemic circulation and site-specific delivery[16, 51]. Functionalization of these lipid-based systems with ligands like peptides or antibodies allows for targeted delivery to inflamed or cancerous tissues, improving therapeutic outcomes in metabolic diseases and obesity-associated cancers. Moreover, these carriers are generally well-tolerated and have been extensively studied in both preclinical and clinical settings, making them attractive candidates for nutraceutical and pharmaceutical applications.

5.3. Dendrimers and Gold Nanoparticles

Dendrimers and gold nanoparticles (AuNPs) represent sophisticated nanocarrier systems that offer enhanced functionality, controlled drug release, and superior targeting abilities[52]. Dendrimers are highly branched, monodisperse macromolecules with a high degree of surface functional groups, making them ideal for conjugating multiple drugs, imaging agents, or targeting moieties[53]. Their unique structure allows them to encapsulate or conjugate polyphenols, improving their solubility, bioavailability, and stability. Dendrimers can be tailored to release drugs in response to pH or redox changes, making them ideal for targeting the tumor microenvironment or inflamed tissues. Gold nanoparticles, on the other hand, are celebrated for their unique optical properties, biocompatibility, and ease of surface modification.[53] They can be functionalized with ligands or antibodies to specifically target overexpressed receptors in diabetic, inflamed, or cancerous tissues. Their small size allows them to penetrate deep into tissues and cells, enhancing intracellular delivery. Both dendrimers and AuNPs have demonstrated improved cellular uptake and reduced systemic toxicity compared to free drug forms[52]. Additionally, their use in imaging and diagnostics offers potential for theranostic applications. These nanocarriers are currently being explored in clinical trials, further validating their potential in targeted therapies for obesity-linked diseases.

5.4. Nanoemulsions and Micelles

Nanoemulsions and micelles are colloidal nanocarrier systems that have garnered significant attention for the delivery of lipophilic antioxidants, particularly in the context of metabolic and oncological disorders[54]. Nanoemulsions are thermodynamically unstable systems consisting of oil droplets dispersed in water, stabilized by surfactants. They typically range in size from 20 to 200 nm and are known for their excellent solubilization capacity and high surface area, which facilitates rapid absorption[54]. Micelles, in contrast, are formed when amphiphilic molecules self-assemble into spherical structures in aqueous environments, with hydrophobic cores that can encapsulate poorly soluble drugs[43]. Both systems significantly improve the bioavailability of polyphenolic compounds such as curcumin, resveratrol, and catechins, which are otherwise limited by poor water solubility. Additionally, they can be modified for targeted delivery, controlled release, and co-delivery of multiple agents. In preclinical models, nanoemulsions and micelles have demonstrated improved antioxidant activity, reduced oxidative stress, and modulation of metabolic markers[5]. These carriers are particularly promising for oral and topical delivery and are easy to scale up for industrial production. Their use in addressing obesity-related oxidative stress and inflammation makes them promising candidates for next-generation therapies.

6. Synergistic Applications in Obesity-Linked Diseases

The integration of nanotechnology-based delivery systems in managing obesity-linked diseases offers a multifaceted therapeutic approach. Obesity is a central risk factor for a range of chronic diseases, including type 2 diabetes, cardiovascular disease, and several cancers. Traditional treatment strategies are often limited by poor drug solubility, systemic side effects, and lack of tissue specificity[55, 56]. Nanotechnology addresses these challenges by enabling precise delivery of bioactive agents, improving their pharmacokinetic profiles, and allowing combinatorial therapies. Through smart design, nanocarriers can be engineered to respond to environmental stimuli like pH, temperature, or enzyme concentration—ensuring the release of therapeutic agents precisely at the disease site[45]. The encapsulation of polyphenols and antioxidants into nanoparticles enhances their therapeutic efficacy, allowing for targeted modulation of inflammation, oxidative stress, and metabolic dysfunction. In diabetes, nanocarriers improve glycemic control and β-cell preservation; in cancer, they enhance chemoprevention and tumor suppression[57]. Dual-targeting systems offer a novel approach by co-delivering agents for both metabolic and oncological pathways. This section outlines how nanotechnology-based interventions can be applied synergistically in various obesity-related pathologies, presenting a promising frontier in integrated and precision therapy for complex metabolic disorders.

6.1. Diabetes Management

Diabetes mellitus, particularly type 2 diabetes, is often associated with obesity and characterized by insulin resistance, chronic inflammation, and β-cell dysfunction[34, 58]. Nanotechnology has shown promise in enhancing the therapeutic efficacy of natural polyphenols such as curcumin and resveratrol, which are known for their antioxidant, anti-inflammatory, and antidiabetic properties[46, 59]. Nano-encapsulation of these compounds in biodegradable carriers like PLGA or lipid-based nanoparticles significantly improves their stability, solubility, and bioavailability. In diabetic animal models, these nanoformulations have demonstrated improved glycemic control, enhanced insulin sensitivity, and protection of pancreatic β-cells from oxidative damage[45, 60]. Furthermore, targeted delivery to pancreatic tissue reduces off-target effects and enhances therapeutic outcomes. Some advanced nanocarriers are also responsive to glucose levels, releasing their payload in hyperglycemic conditions—offering a smart and dynamic approach to diabetes management. Such systems not only reduce the dosing frequency but also maintain drug concentration within the therapeutic window[61]. Clinical translation of these systems could revolutionize diabetes treatment by reducing reliance on synthetic hypoglycemics and minimizing side effects. As nanotechnology continues to evolve, its application in managing metabolic disorders like diabetes holds enormous potential for enhancing patient compliance and clinical outcomes.

6.2. Cancer Prevention and Therapy

Obesity is a known risk factor for various cancers, including breast, colon, and prostate cancers[62]. The chronic inflammation, altered adipokine signaling, and oxidative stress associated with obesity contribute significantly to tumor initiation and progression[3, 21]. Polyphenolic compounds such as epigallocatechin gallate (EGCG) from green tea exhibit potent anticancer properties by modulating signaling pathways, inducing apoptosis, and inhibiting angiogenesis[25]. However, their clinical use is limited by poor bioavailability. Nanocarrier systems, including liposomes, polymeric nanoparticles, and micelles, have been developed to encapsulate these compounds, significantly enhancing their therapeutic index[63]. These nanoformulations increase accumulation in tumor tissues via enhanced permeability and retention (EPR) effect, reduce systemic toxicity, and allow for targeted delivery. In preclinical cancer models, nanocarrier-delivered polyphenols have shown superior tumor inhibition compared to their free forms[62]. Additionally, the potential for co-loading with chemotherapeutic agents opens avenues for combination therapy, enhancing efficacy while mitigating side effects. By leveraging the benefits of nanotechnology, it becomes possible to translate the chemopreventive potential of natural compounds into effective cancer therapies, especially in patients with obesity-driven oncogenesis. These developments represent a promising convergence of nutraceuticals and nanomedicine in modern oncology.

7. Challenges and Future Perspectives

One of the primary challenges in advancing nanocarrier-based antioxidant delivery is navigating the complex regulatory landscape. Securing regulatory approval for nanocarriers remains a formidable hurdle due to the lack of universally accepted standards and the relatively novel nature of these technologies. Regulatory bodies demand comprehensive data on the physicochemical properties, stability, pharmacokinetics, and safety profiles of nanocarriers, which can be difficult to compile due to variability in synthesis and performance. Additionally, concerns surrounding long-term toxicity and immunogenicity must be thoroughly addressed. Nanoparticles may induce immune responses or accumulate in organs, leading to unforeseen side effects. Thus, rigorous preclinical and clinical testing is required to ensure safety, yet these processes are time-consuming and costly. The inherent complexity of these nanosystems further complicates their path to clinical adoption, especially when combined with bioactive antioxidants whose effects can vary based on source and formulation.

Scalability and cost-effectiveness represent additional critical challenges in translating nano-antioxidant technologies from the laboratory to the marketplace. While many nanoparticle formulations show promising efficacy in controlled settings, mass production often proves technically demanding and economically unfeasible. Reproducibility of nanoparticle synthesis at industrial scales without compromising efficacy or stability is a significant concern. Furthermore, the standardization of antioxidant extraction methods and nanoparticle synthesis protocols remains inconsistent across laboratories and production sites, which hampers quality control and batch-to-batch uniformity. Without standardized guidelines, the translation of lab-based research into consistent, scalable, and affordable healthcare solutions becomes nearly impossible. Overcoming these issues requires coordinated efforts among researchers, industry stakeholders, and regulatory agencies to establish unified standards and cost-efficient production frameworks that do not sacrifice the integrity of nanoformulations.

Looking ahead, the future of nano-antioxidant therapy lies in leveraging cutting-edge technologies to refine and personalize treatment approaches. Artificial intelligence (AI) offers unprecedented opportunities for optimizing nanocarrier design, predicting patient-specific responses, and streamlining clinical development. AI algorithms can analyze vast datasets to tailor nanoformulations to individual patient needs, enhancing therapeutic outcomes. Moreover, emerging research into microbiota-targeted delivery systems opens new possibilities for enhancing antioxidant efficacy by directing nanoparticles to specific gut environments. This could offer dual benefits in modulating both oxidative stress and gut health. Furthermore, integrating nano-antioxidants with immunotherapeutic strategies holds promise for comprehensive disease management, particularly in conditions like cancer and chronic inflammation. By combining the anti-inflammatory and cytoprotective properties of antioxidants with immune-modulating therapies, this approach could provide synergistic benefits, paving the way for next-generation precision medicine solutions.

CONCLUSION

Obesity-linked diabetes and cancer pose a global health challenge driven by shared pathogenic mechanisms. Natural antioxidants, empowered by nanotechnology-based delivery systems, offer a promising, safe, and efficient therapeutic strategy. This combinatorial approach addresses both upstream metabolic dysregulation and downstream oncogenic transformation, highlighting a transformative path in precision medicine.

REFERENCES

1. Abdali, D., Samson, S.E., Grover, A.K.: How effective are antioxidant supplements in obesity and diabetes? Med. Princ. Pract. Int. J. Kuwait Univ. Health Sci. Cent. 24, 201–215 (2015). https://doi.org/10.1159/000375305

2. Barber, T.M., Kyrou, I., Randeva, H.S., Weickert, M.O.: Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int. J. Mol. Sci. 22, 546 (2021). https://doi.org/10.3390/ijms22020546
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
5. Karthikeyan, A., Senthil, N., Min, T.: Nanocurcumin: A Promising Candidate for Therapeutic Applications. Front. Pharmacol. 11, (2020). https://doi.org/10.3389/fphar.2020.00487
6. Cheng, Y., Liang, S., Zhang, S., Hui, X.: Thermogenic Fat as a New Obesity Management Tool: From Pharmaceutical Reagents to Cell Therapies. Biomedicines. 12, 1474 (2024). https://doi.org/10.3390/biomedicines12071474
7. Collins, K.H., Herzog, W., MacDonald, G.Z., Reimer, R.A., Rios, J.L., Smith, I.C., Zernicke, R.F., Hart, D.A.: Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity. Front. Physiol. 9, (2018). https://doi.org/10.3389/fphys.2018.00112
8. Hagman, S., Mäkinen, A., Ylä-Outinen, L., Huhtala, H., Elovaara, I., Narkilahti, S.: Effects of inflammatory cytokines IFN-γ, TNF-α and IL-6 on the viability and functionality of human pluripotent stem cell-derived neural cells. J. Neuroimmunol. 331, 36–45 (2019). https://doi.org/10.1016/j.jneuroim.2018.07.010
9. Jahandideh, B., Derakhshani, M., Abbaszadeh, H., Akbar Movassaghpour, A., Mehdizadeh, A., Talebi, M., Yousefi, M.: The pro-Inflammatory cytokines effects on mobilization, self-renewal and differentiation of hematopoietic stem cells. Hum. Immunol. 81, 206–217 (2020). https://doi.org/10.1016/j.humimm.2020.01.004
10. Magadani, R., Ndinteh, D.T., Roux, S., Nangah, L.P., Atangwho, I.J., Uti, D.E., Alum, E.U., Egba, S.I.: Cytotoxic Effects of Lecaniodiscus Cupanioides (Planch.) Extract and Triterpenoids-derived Gold Nanoparticles On MCF-7 Breast Cancer Cell Lines. Anticancer Agents Med. Chem. (2025). https://doi.org/10.2174/0118715206325529241004064307
11. Obisi, J.N., Abimbola, A.N.J., Babaleye, O.A., Atidoglo, P.K., Usin, S.G., Nwanaforo, E.O., Patrick-Inezi, F.S., Fasogbon, I.V., Chimezie, J., Dare, C.A., Kuti, O.O., Uti, D.E., Omeoga, H.C.: Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations. Discov. Oncol. 16, (2025). https://doi.org/10.1007/s12672-025-02102-4
12. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
13. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in monosodium glutamate-obese Wistar rats. Biomed. Pharmacother. Biomedecine Pharmacother. 124, 109879 (2020). https://doi.org/10.1016/j.biopha.2020.109879
14. Orji, O.U., Awoke, N.J., Uti, D.E., Obasi, O.D., Aja, P.M., Nwamaka, E.N., Umoru, G.U., Ogbu, P.N., Udoudoh, M.P., Alum, E.U., Ogbu, C.O., Oodo, S.I., Ibiam, U.A.: The Therapeutic Role of Gastrodin in Combating Insulin Resistance, Inflammation, and Oxidative Stress Induced by Bisphenol-A. Nat. Prod. Commun. 19, 1934578X241310096 (2024). https://doi.org/10.1177/1934578X241310096
15. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
16. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv. Pharm. Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
17. Mohite, P., Singh, S., Pawar, A., Sangale, A., Prajapati, B.G.: Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front. Drug Deliv. 3, (2023). https://doi.org/10.3389/fddev.2023.1232012
18. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
19. Zanbili, F., Poursattar Marjani, A.: Innovative green and bio-based approaches for photosensitive nanoparticle synthesis: a review on methodologies, characterization, and applications. Micro Nano Syst. Lett. 13, 3 (2025). https://doi.org/10.1186/s40486-025-00223-7

20. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
21. Alharbi, H.O.A., Alshebremi, M., Babiker, A.Y., Rahmani, A.H.: The Role of Quercetin, a Flavonoid in the Management of Pathogenesis Through Regulation of Oxidative Stress, Inflammation, and Biological Activities. Biomolecules. 15, 151 (2025). https://doi.org/10.3390/biom15010151
22. Nishida, A., Andoh, A.: The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis. Cells. 14, 488 (2025). https://doi.org/10.3390/cells14070488
23. Mir, M.M., Jeelani, M., Alharthi, M.H., Rizvi, S.F., Sohail, S.K., Wani, J.I., Sabah, Z.U., BinAfif, W.F., Nandi, P., Alshahrani, A.M., Alfaifi, J., Jehangir, A., Mir, R.: Unraveling the Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions. Int. J. Mol. Sci. 26, 2770 (2025). https://doi.org/10.3390/ijms26062770
24. Barber, K., Mendonca, P., Soliman, K.F.A.: The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer's Disease. Brain Sci. 13, 145 (2023). https://doi.org/10.3390/brainsci13010145
25. Feldman, F., Koudoufio, M., Desjardins, Y., Spahis, S., Delvin, E., Levy, E.: Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. Nutrients. 13, 672 (2021). https://doi.org/10.3390/nu13020672
26. Ibiam, U.A.: Antioxidant Effect Of Buchholzia Coriacea Ethanol Leaf-Extract And Fractions On Freund's Adjuvant-Induced Arthritis In Albino Rats: A Comparative Study. Slov. Vet. Res. 59, (2022). https://doi.org/10.26873/SVR-1150-2022
27. Alami, M., Boumezough, K., Zerif, E., Zoubdane, N., Khalil, A., Bunt, T., Laurent, B., Witkowski, J.M., Ramassamy, C., Boulbaroud, S., Fulop, T., Berrougui, H.: In Vitro Assessment of the Neuroprotective Effects of Pomegranate (Punica granatum L.) Polyphenols Against Tau Phosphorylation, Neuroinflammation, and Oxidative Stress. Nutrients. 16, 3667 (2024). https://doi.org/10.3390/nu16213667
28. Clemente-Suárez, V.J., Redondo-Flórez, L., Beltrán-Velasco, A.I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C.C., Tornero-Aguilera, J.F.: The Role of Adipokines in Health and Disease. Biomedicines. 11, 1290 (2023). https://doi.org/10.3390/biomedicines11051290
29. Bocian-Jastrzębska, A., Malczewska-Herman, A., Kos-Kudła, B.: Role of Leptin and Adiponectin in Carcinogenesis. Cancers. 15, 4250 (2023). https://doi.org/10.3390/cancers15174250
30. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
31. Bié, J., Sepodes, B., Fernandes, P.C.B., Ribeiro, M.H.L.: Polyphenols in Health and Disease: Gut Microbiota, Bioaccessibility, and Bioavailability. Compounds. 3, 40–72 (2023). https://doi.org/10.3390/compounds3010005
32. Bešlo, D., Golubić, N., Rastija, V., Agić, D., Karnaš, M., Šubarić, D., Lučić, B.: Antioxidant Activity, Metabolism, and Bioavailability of Polyphenols in the Diet of Animals. Antioxidants. 12, 1141 (2023). https://doi.org/10.3390/antiox12061141
33. Alum, E.U.: Climate change and its impact on the bioactive compound profile of medicinal plants: implications for global health. Plant Signal. Behav. 19, 2419683 (2024). https://doi.org/10.1080/15592324.2024.2419683
34. Bouyahya, A., Balahbib, A., Khalid, A., Makeen, H.A., Alhazmi, H.A., Albratty, M., Hermansyah, A., Ming, L.C., Goh, K.W., El Omari, N.: Clinical applications and mechanism insights of natural flavonoids against type 2 diabetes mellitus. Heliyon. 10, e29718 (2024). https://doi.org/10.1016/j.heliyon.2024.e29718
35. Fatima, N., Baqri, S.S.R., Bhattacharya, A., Koney, N.K.-K., Husain, K., Abbas, A., Ansari, R.A.: Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy. Front. Genet. 12, (2021). https://doi.org/10.3389/fgene.2021.758733
36. Alum, E.U.: Role of phytochemicals in cardiovascular disease management: Insights into mechanisms, efficacy, and clinical application. Phytomedicine Plus. 5, 100695 (2025). https://doi.org/10.1016/j.phyplu.2024.100695
37. Kapała, A., Szlendak, M., Motacka, E.: The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies. Nutrients. 14, 5152 (2022). https://doi.org/10.3390/nu14235152
38. Qi, W.J., Sheng, W.S., Peng, C., Xiaodong, M., Yao, T.Z.: Investigating into anti-cancer potential of lycopene: Molecular targets. Biomed. Pharmacother. 138, 111546 (2021). https://doi.org/10.1016/j.biopha.2021.111546

39. Sahin, K., Orhan, C., Sahin, N., Kucuk, O.: Anticancer Properties of Lycopene. In: Bioactive Molecules in Food. pp. 935–969. Springer, Cham (2019)
40. Azman, M., Sabri, A.H., Anjani, Q.K., Mustaffa, M.F., Hamid, K.A.: Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. Pharmaceuticals. 15, 975 (2022). https://doi.org/10.3390/ph15080975
41. Alum, E.U.: Priming medicinal plants with stress signals: a sustainable approach to boosting therapeutic efficacy. J. Plant Interact. 20, 2500947 (2025). https://doi.org/10.1080/17429145.2025.2500947
42. Hao, Y., Quinnies, K., Realubit, R., Karan, C., Tatonetti, N.P.: Tissue-Specific Analysis of Pharmacological Pathways. CPT Pharmacomet. Syst. Pharmacol. 7, 453–463 (2018). https://doi.org/10.1002/psp4.12305
43. Arora, S., Singh, B., Kumar, S., Kumar, A., Singh, A., Singh, C.: Piperine loaded drug delivery systems for improved biomedical applications: Current status and future directions. Health Sci. Rev. 9, 100138 (2023). https://doi.org/10.1016/j.hsr.2023.100138
44. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
45. Jalili, A., Bagherifar, R., Nokhodchi, A., Conway, B., Javadzadeh, Y.: Current Advances in Nanotechnology-Mediated Delivery of Herbal and Plant-Derived Medicines. Adv. Pharm. Bull. 13, 712–722 (2023). https://doi.org/10.34172/apb.2023.087
46. Krsek, A., Baticic, L.: Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer's and Parkinson's Disease. Future Pharmacol. 4, 352–379 (2024). https://doi.org/10.3390/futurepharmacol4020020
47. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
48. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
49. Sivadasan, D., Sultan, M.H., Madkhali, O., Almoshari, Y., Thangavel, N.: Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform—A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications. Pharmaceutics. 13, 1291 (2021). https://doi.org/10.3390/pharmaceutics13081291
50. Shehata, M.M.: Anticancer lipid-based drug delivery systems: Basic knowledge and recent applications. Nano TransMed. 3, 100054 (2024). https://doi.org/10.1016/j.ntm.2024.100054
51. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
52. Kalomiraki, M., Thermos, K., Chaniotakis, N.A.: Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int. J. Nanomedicine. 11, 1–12 (2015). https://doi.org/10.2147/IJN.S93069
53. Mittal, P., Saharan, A., Verma, R., Altalbawy, F.M.A., Alfaidi, M.A., Batiha, G.E.-S., Akter, W., Gautam, R.K., Uddin, Md.S., Rahman, Md.S.: Dendrimers: A New Race of Pharmaceutical Nanocarriers. BioMed Res. Int. 2021, 8844030 (2021). https://doi.org/10.1155/2021/8844030
54. Ashaolu, T.J.: Nanoemulsions for health, food, and cosmetics: a review. Environ. Chem. Lett. 19, 3381–3395 (2021). https://doi.org/10.1007/s10311-021-01216-9
55. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
56. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African walnuts (Tetracarpidium conophorum) modulate hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase. Endocr. Metab. Immune Disord.-Drug Targets Former. Curr. Drug Targets-Immune Endocr. Metab. Disord. 20, 365–379 (2020)
57. Abdelazim, K., Ghit, A., Assal, D., Dorra, N., Noby, N., Khattab, S.N., El Feky, S.E., Hussein, A.: Production and therapeutic use of astaxanthin in the nanotechnology era. Pharmacol. Rep. 75, 771–790 (2023). https://doi.org/10.1007/s43440-023-00488-y
58. Adhikari, B.: Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. J. Chem. 2021, 2691525 (2021). https://doi.org/10.1155/2021/2691525

59. Gunasena, M.D.K.M., Galpaya, G.D.C.P., Abeygunawardena, C.J., Induranga, D.K.A., Priyadarshana, H.V.V., Millavithanachchi, S.S., Bandara, P.K.G.S.S., Koswattage, K.R.: Advancements in Bio-Nanotechnology: Green Synthesis and Emerging Applications of Bio-Nanoparticles. Nanomaterials. 15, 528 (2025). https://doi.org/10.3390/nano15070528
60. Kumarasamy, R.V., Natarajan, P.M., Umapathy, V.R., Roy, J.R., Mironescu, M., Palanisamy, C.P.: Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. Front. Nanotechnol. 6, (2024). https://doi.org/10.3389/fnano.2024.1479993
61. Zhang, T., Tang, J.Z., Fei, X., Li, Y., Song, Y., Qian, Z., Peng, Q.: Can nanoparticles and nano–protein interactions bring a bright future for insulin delivery? Acta Pharm. Sin. B. 11, 651–667 (2021). https://doi.org/10.1016/j.apsb.2020.08.016
62. Obesity and Cancer Fact Sheet - NCI, https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet
63. Poudwal, S., Misra, A., Shende, P.: Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists. J. Drug Target. 29, 834–847 (2021). https://doi.org/10.1080/1061186X.2021.1894434

CITE AS: Omeye Francis I. (2025). Targeting Obesity-Linked Diabetes and Cancer: Synergistic Roles of Natural Antioxidants and Nanotechnology-Based Drug Delivery Systems. EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES, 6(3):29-38